Recce Ltd has released a press release.
R327 Efficacy against WHO Priority Pathogen Acinetobacter B
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Placement & SPP to raise $10 million - Funded to FY26
- Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
- Ethics Approval Broadens to All Topical Infections
- Further R&D Rebate Approved
- R327 added to WHO List of Antibacterial Products
Later from Recce Pharmaceuticals
- US Department of Defense Grants US $2m for R327G
- Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
- Successful Completion of Share Purchase Plan
- Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
- Notice of Special General Meeting/Proxy Form
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals